Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aduro wants to run but is hamstringed by Advaxis. Advaxis is best in class and is continually getting a mop handle shoved where the sun doesn't shine. Sorry Aduro but your not going anywhere without your best in class patriarch!
The guy is like a lot of our politicians, there's no limit to his greed and no depth that he will not dive for a dollar.
I totally agree FBG, the guy is a crook!
Dan didn't lose anything.
HFT gives the wealthy a tool to rape innovative companies. That's what's been happening to advaxis. No person or group of persons should have that power
I think it's a great thing to put it out there beforehand!
It tells is they don't think we'll ever be near the strike price again. Buying these now before a data release is dang good to see.
I think Adaxis has the best approach to harnessing the immune system out there be it for cancer treatment or ID. Nobody else comes close.
I would be okay with it but I doubt Dan and management would be.
I agree, it's a way for them to spend company money on themselves. It doesn't mean anything until we see the Data. Failure to launch fully defines Dan.
It's not too often you see a drug, let alone a platform tech that has slam dunk safety and effectiveness. That might a clue as to why we are manipulated like we are.
I do believe in it, I really think the high dose study and the combo check point inhibitor trials will make a dramatic difference in the ability to get PRs and CRs going forward. Maybe we will get some surprising data at the conferences coming up. I definitely would not want to be short.
Yeah, it should be interesting to the results of the combination therapy with Astra.
That is something to think about, remember Dr. Mason said this vaccine has to be front loaded properly as this population of patients including the HER2 dogs are the sickest of the sick and don't have time to be dosed over time. The high dose is ten times the strength of the dose that was used in the gog study and is being tolerated very well.
So the GRU study was expanded to another 15 patients, is the expansion phase being treated with the 1×10 to the 10th. I assume it was expanded due to the tolerability and partial responder who is still alive and getting dosed?
We may be too tech heavy for one company to buy.
That's not enough to get the job done!
Don't forget after the shananigans they put in place a code of conduct. That's pretty much admitting you did something immoral and are now preventing anyone else from doing the same.
If our studies were not purposefully interfered with by the FDA, AXAL would have already been touted as a cure. That's not my opinion, that's our destiny, God love Yvonne Patterson, a fantastic woman!
I wonder if it would be possible to sell licensing rights to multiple companies. License it with SOC and with Astra? It would be infinitely more valuable that way. I could also see the company licensing Axal and the PSA construct being licensed to different companies at the same time. If they want to both buy shares. It might be real hard to pull us back to these levels if another deal is cut.
Sounds about right FBG, you would think the stock would be worth more after the Amgen deal, after all it was sold at 13.50 immediately afterwards. I don't know how the price of the stock is supposed to appreciate when Dan is more then willing to sell at whatever price any pharmaceutical company is willing to offer?!?!?!.
They know it will flat out cure cancer if allowed to be given via the protocol that was used in GOG.
Very funny that advaxis announces killer trial results this AM and the market is treating us like we are Aduro! You just can't make this stuff up, LOL!
I'd probably take it as well FBG, we have a CEO that has been extremely nefarious with share holders so I would take the money and run. Let Dan figure out how he would stop his cash cow from being stolen for next to nothing.
That's the problem in dealing with shareholders in the manner he has, we start thinking about putting our own welfare first and quit supporting someone who has made the company into his own piggy bank.
I'd love to see someone swoop in and steal AXAL and the PSA construct while Astra and Merck stand silently trying to rape Advaxis. Amgen high lighted the fact that this is a real possibility! They got a great deal on a cure for cancer that is still preclinical. It'll happen if those two wait any longer.
I'm curious as to what dose they went with in regard to the combo trial with Merck for PSA?
Pretty sure big pharma is shorting us through investment bankers and they keep dragging us down to this level so Dan will hand over another portion of the company for peanuts. Dan can't stop himself and thinks selling shares with every deal is a great thing not being intelligent enough to realize he is diluting everyone who holds stock including himself
If that's not what it implies then I don't know what it implies. Pretty sure James is spot on regarding this.
I really think Amgen partnering with and completely funding MINE will force a lot of checkpoint companies to the table. MINE will dominate cancer treatment so these companies need combo therapy to compete.
The first clue that the fau legal maneuver is nothing more then a short trying to get out of their I'll advised position is that this is nothing more then an investigation. You can't get anything from the company by stating you are investigating their management's behavior. This is nothing more then someone frantically trying to get out of a position that could well bankrupt them!
I'm telling you if we get approved in EU early and the rest of our platform is as safe and effective Astrazeneca will Pony up. The rest of our constructs could also very easily approved early. AXAL, if approved early could pay for the expense of buying the whole company.
I've Posted before, I don't expect our P3 to start with the current format where we are being used as an adjuvant to the SOC. I think we will see a ya or na in Europe before any P3 starts. We work better then SOC alone so unless being used as an adjuvant is the fastest route to income, I don't see it happening. If we are able to gain access to the European markets, I could also see the company being bought. I think interest may have already been expressed recently with the changes being made at Advaxis. JMO
Just throwing this out there, take it for what it's worth....
Upper management in the company is being restructured, management hasn't bought any shares this month either.
Mayes is delving into infectious disease something the company hasn't talked about in a long time.
Anyone thinking the new COO is being groomed to take over under new ownership, I mean, I really don't think Dan would take Greg out of that position unless there was a pot of gold at the end of the rainbow for both Greg and Dan.
Those shares didn't have voting rights, the company kept the voting rights. Dan making sure nobody steals the company out from under him. A good indicator that the company could be worth enough to warrant a hostile takeover.
10/10 is my B-day, so maybe Advaxis will give me a big fat surprise.
I bought quite a few shares in the eights when I was screaming the share price was retard cheap, the SP took off and I picked up quite a few more at 10.69. I felt real good about getting them there. I've bought a few more over the past couple of days as it occurs to me our little bio is about to undergo a transformation that will make folks wish they could get shares for 10.69.
Fantastic insightful post. Thank you!
The CAT recommendation could potentially gain us access to European markets very soon. This is a market Aduro can never enter as EU courts ruled they were infringing on our patents. Another reason our MC should be twice theirs or more.
Next week I me meant to say.
Keep in mind next CAT could potentially make its recommendation.